Exicure, Inc. (NASDAQ:XCUR) Sees Significant Drop in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 27,500 shares, a decrease of 19.8% from the March 31st total of 34,300 shares. Based on an average daily volume of 41,100 shares, the short-interest ratio is currently 0.7 days. Currently, 3.3% of the company’s shares are short sold.

Exicure Price Performance

Exicure stock opened at $10.73 on Friday. The firm has a 50-day moving average of $11.65 and a two-hundred day moving average of $11.54. Exicure has a 1 year low of $1.44 and a 1 year high of $36.00. The stock has a market cap of $67.79 million, a price-to-earnings ratio of -5.18 and a beta of 3.74.

Exicure (NASDAQ:XCUR) last issued its earnings results on Tuesday, March 18th. The company reported ($3.39) earnings per share for the quarter.

Hedge Funds Weigh In On Exicure

An institutional investor recently raised its position in Exicure stock. Carlyle Group Inc. lifted its position in Exicure, Inc. (NASDAQ:XCUR) by 400.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 281,636 shares of the company’s stock after buying an additional 225,308 shares during the period. Exicure makes up about 0.9% of Carlyle Group Inc.’s portfolio, making the stock its 11th largest position. Carlyle Group Inc. owned approximately 10.79% of Exicure worth $3,850,000 at the end of the most recent reporting period. 42.82% of the stock is owned by institutional investors.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.